MAD2L2 and cancer: There is a significant association between high levels of REV7 expression and poor prognosis in several tumors, including colon, breast, lung, gastric, and advanced ovarian cancers, diffuse large B cell lymphomas, and advanced bone and soft tissue sarcomas, suggesting the utility of REV7 as a biomarker for cancer prognosis [85,87,88,89,94,96,97].